Literature DB >> 7853796

Improved treatment of thrombosed hemodialysis access sites with thrombolysis and angioplasty.

M A Cohen1, D A Kumpe, J D Durham, S C Zwerdlinger.   

Abstract

We treated percutaneously 135 expanded polytetrafluoroethylene (PTFE) prosthetic grafts which had thrombosed using thrombolysis with urokinase followed by balloon angioplasty. Functional patency was re-established in 38 of 62 (61%) using single catheter technique, and in 62 of 73 (85%) using crossed catheter technique (P < 0.01). Hemorrhagic complications were reduced from 12.9% in the single catheter technique to 1.4% in the crossed catheter technique (P < 0.01). Median "primary patency after treatment" of the PTFE accesses after successful restoration of function was 98 days. Cumulative "primary patency after treatment" from the time of successful recanalization of the thrombosis for the PTFE grafts was 70.5% at one month, 45.8% at 6 months, and 16.2% at 12 months. Among a smaller group of 26 PTFE patients who were treated with only interventional radiologic procedures (repeat thrombolysis and/or angioplasty), without surgical revision, "secondary patency after treatment" from the time of thrombosis was 92.3% at 1 month, 80.2% at 6 months, 69.4% at 12 months, and 36.5% at 24 months. We conclude that lysis/angioplasty is a valuable means of treating thrombosed hemodialysis access sites. The crossed catheter technique produces superior initial technical success compared with single catheter infusion of the lytic agent. "Primary patency after treatment" after successful recanalization is relatively short, but long-term patency is improved substantially with retreatment of recurrent failure of the access with repeat thrombolysis and/or angioplasty.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7853796     DOI: 10.1038/ki.1994.407

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

1.  Endovascular management of immediate procedure-related complications of failed hemodialysis access recanalization.

Authors:  Dong Hun Kim; Dong Erk Goo; Seung Boo Yang; Cheul Moon; Deuk Lin Choi
Journal:  Korean J Radiol       Date:  2005 Jul-Sep       Impact factor: 3.500

2.  Pharmacomechanical Thrombolysis of Dialysis Access Grafts Using the MTI Castañeda Over-the-Wire Brush Catheter and Reteplase.

Authors:  Alexjandro Mendez-Castillo; Syed Hassain; Flavio Castañeda
Journal:  Semin Intervent Radiol       Date:  2004-06       Impact factor: 1.513

Review 3.  Hemodialysis vascular access monitoring: current concepts.

Authors:  Michael Allon; Michelle L Robbin
Journal:  Hemodial Int       Date:  2009-04       Impact factor: 1.812

4.  Efficacy of a modified pharmacomechanical thrombolysis technique for endovascular treatment of thrombosed prosthetic arteriovenous grafts.

Authors:  Sun Young Choi; Byung Gil Choi; Kum Hyun Han; Ho Jong Chun
Journal:  Korean J Radiol       Date:  2012-04-17       Impact factor: 3.500

5.  Temporal distribution and biological determinants of thrombotic events after interventions for dialysis vascular access.

Authors:  Mu-Yang Hsieh; Chih-Kuo Lee; Chien-Ming Lo; Chiu-Hui Chen; Shao-Yuan Chuang; Chih-Cheng Wu
Journal:  Sci Rep       Date:  2019-07-24       Impact factor: 4.379

6.  [Safety and Efficacy of the Percutaneous Manual Aspiration Thrombectomy Technique to Treat Thrombotic Occlusion of Native Arteriovenous Fistulas for Hemodialysis].

Authors:  Sang Eun Yoon; Sun Young Choi; Soo Buem Cho
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2020-01-09

7.  Management of venous hypertension following arteriovenous fistula creation for hemodialysis access.

Authors:  Varun Mittal; Aneesh Srivastava; Rakesh Kapoor; Hira Lal; Tarun Javali; Sanjoy Sureka; Nitesh Patidar; Sohrab Arora; Manoj Kumar
Journal:  Indian J Urol       Date:  2016 Apr-Jun

8.  Clinical outcome of percutaneous thrombectomy of dialysis access thrombosis by an interventional nephrologist.

Authors:  Hyung-Seok Lee; Pyoung-Ju Park
Journal:  Kidney Res Clin Pract       Date:  2014-12-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.